Literature DB >> 26676600

Predictors of normal and abnormal outcome in clinical brain dopamine transporter imaging.

Elina Jaakkola1,2, Juho Joutsa3,4,5, Valtteri Kaasinen3,4.   

Abstract

Brain dopamine transporter (DAT) imaging with [(123)I]FP-CIT SPECT can be used to evaluate the integrity of the mesostriatal dopaminergic system in patients with clinically uncertain parkinsonism. To evaluate whether scanning a patient is clinically necessary, it is vital to understand possible factors that affect the scanning result. Therefore, we investigated an unselected sample of 538 consecutively scanned patients from a 6-year period, and the demographic data and indications for DAT SPECT were recorded. After scanning, the patients were divided into groups according to the scanning outcome. Multivariate binary logistic regression analyses were performed to investigate whether the pre-imaging variables had independent associations with the outcome of the scan. Three hundred and three (56.3 %) patients had abnormal scans showing a dopaminergic deficit. The independent factors associated with abnormal scans were older age (p = 0.002), asymmetry of motor symptoms (p = 0.005) and shorter symptom duration (p < 0.001). Re-evaluation of the previously established Parkinson's disease diagnosis was associated with a higher probability of an abnormal scan (74.4 % abnormal, p = 0.004), whereas the possibility of medication-induced parkinsonism was associated with a higher probability of a normal scan (35.4 %, p = 0.036). The probability of an abnormal outcome in clinical brain DAT imaging increases with known risk factors of neurodegenerative parkinsonism. However, a long duration of uncertain motor symptoms and suspicion of medication-induced parkinsonism are associated with a higher probability of a normal outcome. The findings reflect epidemiological factors in parkinsonism together with referral biases that may be used to improve the clinical use of DAT imaging.

Entities:  

Keywords:  DAT; Parkinsonism; Parkinson’s disease; SPECT

Mesh:

Substances:

Year:  2015        PMID: 26676600     DOI: 10.1007/s00702-015-1495-0

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  15 in total

Review 1.  The mystery of motor asymmetry in Parkinson's disease.

Authors:  Ruth Djaldetti; Ilan Ziv; Eldad Melamed
Journal:  Lancet Neurol       Date:  2006-09       Impact factor: 44.182

2.  Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts.

Authors:  Julia Kraemmer; Gabor G Kovacs; Laura Perju-Dumbrava; Susanne Pirker; Tatiana Traub-Weidinger; Walter Pirker
Journal:  Mov Disord       Date:  2014-07-22       Impact factor: 10.338

3.  Differences in striatal dopamine transporter density between tremor dominant and non-tremor Parkinson's disease.

Authors:  Valtteri Kaasinen; Maija Kinos; Juho Joutsa; Marko Seppänen; Tommi Noponen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-28       Impact factor: 9.236

4.  Topography of dopamine transporter availability in progressive supranuclear palsy: a voxelwise [123I]beta-CIT SPECT analysis.

Authors:  Klaus Seppi; Christoph Scherfler; Eveline Donnemiller; Irene Virgolini; Michael F H Schocke; Georg Goebel; Katherina J Mair; Sylvia Boesch; Christian Brenneis; Gregor K Wenning; Werner Poewe
Journal:  Arch Neurol       Date:  2006-08

5.  Effects of aging and gender on striatal and extrastriatal [123I]FP-CIT binding in Parkinson's disease.

Authors:  Valtteri Kaasinen; Juho Joutsa; Tommi Noponen; Jarkko Johansson; Marko Seppänen
Journal:  Neurobiol Aging       Date:  2015-01-22       Impact factor: 4.673

Review 6.  Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates.

Authors:  Timothy J Collier; Nicholas M Kanaan; Jeffrey H Kordower
Journal:  Nat Rev Neurosci       Date:  2011-05-18       Impact factor: 34.870

7.  Role of DaTSCAN and clinical diagnosis in Parkinson disease.

Authors:  Raúl de la Fuente-Fernández
Journal:  Neurology       Date:  2012-02-08       Impact factor: 9.910

8.  Some specific clinical features differentiate multiple system atrophy (striatonigral variety) from Parkinson's disease.

Authors:  C Colosimo; A Albanese; A J Hughes; V M de Bruin; A J Lees
Journal:  Arch Neurol       Date:  1995-03

9.  EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2.

Authors:  Jacques Darcourt; Jan Booij; Klaus Tatsch; Andrea Varrone; Thierry Vander Borght; Ozlem L Kapucu; Kjell Någren; Flavio Nobili; Zuzana Walker; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02       Impact factor: 9.236

Review 10.  Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes.

Authors:  Nin Bajaj; Robert A Hauser; Igor D Grachev
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-03-13       Impact factor: 10.154

View more
  3 in total

1.  Visual versus automated analysis of [I-123]FP-CIT SPECT scans in parkinsonism.

Authors:  Elina Mäkinen; Juho Joutsa; Jarkko Johansson; Maija Mäki; Marko Seppänen; Valtteri Kaasinen
Journal:  J Neural Transm (Vienna)       Date:  2016-06-20       Impact factor: 3.575

Review 2.  Dopamine Transporter Imaging, Current Status of a Potential Biomarker: A Comprehensive Review.

Authors:  Giovanni Palermo; Sara Giannoni; Gabriele Bellini; Gabriele Siciliano; Roberto Ceravolo
Journal:  Int J Mol Sci       Date:  2021-10-18       Impact factor: 5.923

3.  Individual parkinsonian motor signs and striatal dopamine transporter deficiency: a study with [I-123]FP-CIT SPECT.

Authors:  Elina Mäkinen; Juho Joutsa; Elina Jaakkola; Tommi Noponen; Jarkko Johansson; Miia Pitkonen; Reeta Levo; Tuomas Mertsalmi; Filip Scheperjans; Valtteri Kaasinen
Journal:  J Neurol       Date:  2019-01-28       Impact factor: 4.849

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.